## **Humber Area Prescribing Committee**

**Date / Time** 2<sup>nd</sup> October 2024 13:00- 15:00

Venue MS Teams

Chair Dr Sergio Raise

Notes / Action Points Jane Morgan – Principal Pharmacist, HUTH

Quorate: Yes / No No

Attendance Dr Sergio Raise, ERY sub-locality GP Prescribing Lead (SR)

Jane Morgan, Principal Pharmacist - Formulary, Interface and Medicines Commissioning, HUTH (JM)

Luke Storr - Senior Pharmacy Technician, HUTH (LS)

Andrew Karvot - Advanced Clinical and Northern Lincolnshire Interface Pharmacist, NLAG (AK)

Laura Bulmer, Pharmacy Technician Project Manager, NECS (LB)

Kevin McCorry, Senior Medicines Optimisation Pharmacist, NECS (KMc)

Natasha Suffill- Lead Clinical Pharmacist CHCP (NS)

Prof A Morice, Professor of Respiratory Medicine HUTH- (AM)

Dr Weeliat Chong – Chief Pharmacist, Humber Teaching NHS Foundation Trust (WC)

Dr Rolan Schreiber – Medical Secretary, Humber LMC(RSx)

Anna Grocholewska – Chief Pharmacist and MSO, NAVIGO (AGM)

Manjeet Kaur-Deputy Chief Pharmacist, Rotherham, Doncaster and South Humber Foundation Trust (MK)

Paulash Haider- Deputy chief pharmacist, NLAG- (PH) (attending for Joanne Goode).

Oliver Fillingham- Medicines optimisation Pharmacist, NECS- (OF) (attending for Catherine Smith).

Paula Russell- Principal Pharmacist RDTC (PR) (attending for Daniel Newsome)

Dr Pratik Basu- GP- The Birches medical practice (PB)

Jeeten Raghwani – GP- Greenlands Surgery (JR)

**Apologies** Daniel Newsome- Principal Pharmacist RDTC (DN)

Caroline Hayward- Professional Development Pharmacist, Humber Local Pharmaceutical Committee (CH)

Joanne Goode – Chief Pharmacist Humber Health Partnership – HUTH/NLAG (JG)

| Agenda<br>Number | Item                        | Discussion   | Action  | Lead | Due<br>Date |
|------------------|-----------------------------|--|---------|------|-------------|
| 2024.10.01       | Apologies                   | Noted above  |         |      |             |
| 2024.10.02       | Declarations of interest    | Nil  |         |      |             |
| 2024.10.03       | Minutes of previous meeting | Accepted as true record  |         |      |             |
| 2024.10.04       | Action Tracker              | Outstanding actions from HERPC Renal repatriation: November update – JM to meet with renal still; contacted business manager and clinical lead for renal medicine. To update further next time. December update – Not met with renal yet. March update – Updating business case. May update – to meet with NHSE August update – not yet met with NHSE September update: not yet met with NHSE October update: not yet met with NHSE November update: not yet met with NHSE December update: meeting arranged with NHSE February update: meeting arranged and business case in progress April 2024 update: JM and LA met with Paul McManus to discuss further. May 2024 update: business case ongoing July 2024 update: ongoing August 2024 update: ongoing September 2024 update: meeting with NHSE again to discuss. October 2024 update: HUTH have regular meeting with NHSE and updating business case. Outstanding actions from HERPC: Rheumatology to prepare pathway with rituximab without MTX August update: received NLAG pathway which includes this but not received HUTH pathway. Shared NLAG pathway with | Ongoing | JM   | 10/24       |

| pathway for HUTH on D&TC action tracker. To discuss at          |           |            |       |
|---|-----------|------------|-------|
| September D&TC if Dr Ogumbambi in attendance and to             |           |            |       |
| contact to confirm place in pathway, to enable JM to start      |           |            |       |
| writing paper.  |           |            |       |
| September update: September D&TC next week, further             |           |            |       |
|   |           |            |       |
| updates to pathway needed                                       |           |            |       |
| October update: Awaiting updated pathway                        |           |            |       |
| November update: Pathway needs further updates as new TAs       |           |            |       |
| published again and pharmacist who is updating has prioritised  |           |            |       |
| adalimumab switch.  |           |            |       |
| December update: ongoing  |           |            |       |
| February 2024 update: JG to follow up with Dr Ogumbambi         |           |            |       |
| March 2024 update: JG raised at HUTH D&TC to bring NLAG         |           |            |       |
| RA pathway to next guideline group and invite Dr Alvi.          |           |            |       |
| April 2024 update: NLAG RA pathway on agenda                    |           |            |       |
| May 2024 update: HUTH RA pathway currently circulating          |           |            |       |
| rheumatologists for comment.                                    |           |            |       |
| July 2024 update: HUTH RA pathway updates in progress           |           |            |       |
| following comments  |           |            |       |
| August 2024 update: updates completed and send back around      |           |            |       |
| rheumatologists   |           |            |       |
| September 2024 update: Updates still ongoing                    |           |            |       |
| October 2024 update: to close on this tracker and not take      |           |            |       |
| forward to new APC (as on HUTH D&T tracker and needs to go      |           |            |       |
| to D&T prior to APC).   |           |            |       |
| Ratification of guidelines and SCFs                             | Ongoing   | JM         | 10/24 |
| To add information around initial supply of devices to erectile |           |            |       |
| dysfunction following prostatectomy guidance                    |           |            |       |
| April 2024 update: ongoing                                      |           |            |       |
| May 2024: ongoing   |           |            |       |
| July 2024: ongoing  |           |            |       |
| October 2024: to upload guidance                                |           |            |       |
| Ratification of guidelines and SCFs                             | Ongoing   | JM         | 10/24 |
| To upload erectile dysfunction following prostatectomy to       | Crigoring | Olvi       | 10/21 |
| website and update formulary when uploaded                      |           |            |       |
|   |           |            |       |
| April 2024 update: ongoing May 2024: ongoing                    |           |            |       |
| July 2024: ongoing  |           |            |       |
| October 2024: to upload guidance                                |           |            |       |
| Ratification of joint formulary                                 | Ongoing   | IM/I S/AIZ | 11/24 |
|   | Ongoing   | JM/LS/AK   | 11/24 |
| Update joint formulary with chapter 11                          |           |            |       |

|   |  |  | •   |  |
|---|--|--|---|--|
|   | September 2024 update: ongoing October 2024 update: ongoing Ratification of joint formulary To update chapter 14 on joint formulary October 2024 update: ongoing   | Ongoing  | JM/AK   | 11/24  |
|   | Ratification of guidelines and SCFs  | Ongoing  | JM  | 11/24  |
|   | RDTC updates   | Ongoing  | AK  | 11/24  |
|   | RDTC updates   | Ongoing  | JM  | 11/24  |
| Traffic Light Status  | September 2024 TLS- Nil  | Recommendation to IPMOC  | JM  | 11/24  |
|   | <b>Freestyle libre 3-</b> request for transfer of funding recommended to IPMOC. Freestyle libre 3 is currently supplied by hospital specialist teams to a group of patients who require more enhanced care.  |  |   |  |
| Feedback from Integrated<br>Medicines Optimisation<br>Committee | <ul><li>Update on valproate</li><li>7 day script dispensing</li></ul>  | Noted  |   |  |
| Work plans  | <ul><li>a) Joint formulary alignment</li><li>b) Shared care frameworks</li><li>c) Guidelines</li></ul>   | Ongoing for information only   |   |  |
| Ratification of joint formulary                                 | Chapter 15 approved  | To update joint formulary  | JM/LS/AK  | 10/24  |
| Ratification of guidelines and SCFs                             | <ul> <li>a) Methotrexate tablets SCF – updated SCF in line with RMOC guidance. PR noticed an error within monitoring, JM to correct. JM highlighted changes from version reviewed at guideline group around blood borne virus monitoring, tuberculosis screening and raised a query around renal function at initiation. JM to check Yorkshire regional guidance and evidence base around current SCF recommendations.</li> <li>b) Mycophenolate SCF – updated SCF in line with RMOC guidance.</li> <li>c) Hydroxychloroquine SCF – New ICB wide SCF. JM to feedback to Rachel Ainger.</li> <li>d) Lithium Navigo SCF – AGM presented the updates to the lithium SCF for Navigo patients.</li> </ul> | a) Approved pending clarification b) Approved and to upload c) To feedback to RA d) Approved and to upload e) Approved for Hull/ERY and to upload. f) Move to APC template and approved  | JM JM JM JM JM JM   | 11/24<br>11/24<br>11/24<br>11/24<br>11/24<br>11/24 |
|   | Feedback from Integrated Medicines Optimisation Committee Work plans  Ratification of joint formulary Ratification of guidelines   | October 2024 update: ongoing Ratification of joint formulary To update chapter 14 on joint formulary October 2024 update: ongoing Ratification of guidelines and SCFs To finalise 3 ADHD medicines SCFs and upload on APC site RDTC updates To update netFormulary with RDTC updates RDTC updates To update HERPC red list and joint formulary  Traffic Light Status  Freestyle libre 3- request for transfer of funding recommended to IPMOC. Freestyle libre 3 is currently supplied by hospital specialist teams to a group of patients who require more enhanced care.  Feedback from Integrated Medicines Optimisation Committee  Work plans  Patification of joint of Guidelines and SCFs  A) Joint formulary alignment b) Shared care frameworks c) Guidelines  A) Joint formulary alignment b) Shared care frameworks c) Guidelines A) Methotrexate tablets SCF – updated SCF in line with RMOC guidance. PR noticed an error within monitoring, JM to correct. JM highlighted changes from version reviewed at guideline group around blood borne virus monitoring, tuberculosis screening and raised a query around renal function at initiation. JM to check Yorkshire regional guidance and evidence base around current SCF recommendations. b) Mycophenolate SCF – updated SCF in line with RMOC guidance. c) Hydroxychloroquine SCF – New ICB wide SCF. JM to feedback to Rachel Ainger. d) Lithium Navigo SCF – AGM presented the updates to | October 2024 update: ongoing Ratification of joint formulary To update chapter 14 on joint formulary October 2024 update: ongoing Ratification of guidelines and SCFs To finalise 3 ADHD medicines SCFs and upload on APC site RDTC updates To update erformulary with RDTC updates RDTC updates To update HERPC red list and joint formulary  September 2024 TLS- Nil  Freestyle libre 3- request for transfer of funding recommended to IPMOC. Freestyle libre 3 is currently supplied by hospital specialist teams to a group of patients who require more enhanced care.  Feedback from Integrated Medicines Optimisation Committee  Work plans  a) Joint formulary alignment b) Shared care frameworks c) Guidelines Autification of guidelines and SCFs  Ratification of guidelines Autification of guidelines and SCFs  Abethory around plant function at initiation. JM to check Yorkshire regional guidance and evidence base around current SCF recommendations. b) Mycophenolate SCF – updated SCF in line with RMOC guidance. c) Hydroxychloroquine SCF – New ICB wide SCF. JM to feedback to RAchel Alnger. c) Hydroxychloroquine SCF – New ICB wide SCF. JM to feedback to RAchel Alnger. d) Move to APC template and | October 2024 update: ongoing                       |

|            |                                    | <ul> <li>e) Melatonin in adults – JM and AGM presented the new SCF for melatonin in adults. Hull and East Riding currently have an out of date melatonin SCF covering both children and adults; there is currently no SCF in NEL/NL and hence treated as red drug. New SCF approved for use in Hull/ERY but need to review funding in NEL/NL. AGM to run prescribing report from Navigo and discuss patient numbers with OF.</li> <li>f) Opioid conversion chart – JM to add wording to highlight variability in codeine/dihydrocodeine conversion and update references as per CHCP request. To transfer on to HAPC template.</li> <li>g) Testosterone in low libido – NS presented updates to this guidance. Guidance approved and to move onto HAPC template.</li> <li>h) CHCP wound formulary – NS presented updates to CHCP wound formulary that related to change in prescribing guidance for povidone iodine dressings in patients with renal impairment.</li> </ul> | g) Move to APC template and approved h) Approved and to upload  | JM       | 11/24 |
|------------|------------------------------------|---|---|----------|-------|
| 2024.10.10 | HAPC Newsletter                    | July-September 2024   | Attached for information only   |          |       |
| 2024.10.11 | RDTC updates                       | • July 2024   | Update formulary/red list   | JM/LS/AK |       |
| 2024.10.12 | Minutes from subcommittees         | a) Joint formulary subcommittee (Nil)     b) Guideline subcommittee (July 24)   | Attached for info only  |          |       |
| 2024.10.13 | Additional minutes for information | a) HUTH D&TC (Nil) b) HFT DTG (Nil) c) NLAG M&T (July 24) d) NYY APC (July 24)  | Attached for info only  |          |       |
| 2024.10.14 | Correspondence received            | Nil this month  |   |          |       |
| 2024.10.15 | AOB                                | DOACS – JM raised that the national commissioning document for DOACs has been updated to reflect generic availability of rivaroxaban. To update formulary to match this and review guidance. PH highlighted that dabigatran is now also available generically so the national commissioning document may change again.  | To update joint formulary to reflect commissioning position of rivaroxaban. To update anticoagulation guidance. | JM       | 11/24 |
| 2024.10.16 | Date of next meeting               | 6 <sup>th</sup> November- New prescribing committee   |   |          |       |